Related Experiment Video

Updated: Apr 16, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

The -844 G>A PAI-1 polymorphism is associated with acute coronary syndrome in Mexican population

Ilian Janet García-González1, Yeminia Valle2, Elena Sandoval-Pinto3

  • 1Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico ; Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico.

Disease Markers
|March 20, 2015
PubMed

Insights

The -844 G>A polymorphism in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with an increased risk of acute coronary syndrome (ACS). The A allele and AA genotype are identified as risk factors for ACS and potentially dyslipidemia.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Acute coronary syndrome (ACS) poses a significant public health challenge due to high morbidity and mortality.
  • Prothrombotic and proinflammatory states are key in ACS pathogenesis.
  • Plasminogen activator inhibitor-1 (PAI-1) regulates fibrinolysis and immune responses.

Purpose of the Study:

  • To investigate the association between the -844 G>A PAI-1 gene polymorphism and ACS.
  • To determine if this polymorphism influences PAI-1 protein levels, contributing to ACS risk.

Main Methods:

  • A case-control study involving 646 individuals from Western Mexico.
  • Included 350 healthy controls and 296 patients diagnosed with ACS.
  • Genotyping for the -844 G>A PAI-1 polymorphism was performed.

Main Results:

  • Hypertension and smoking were the primary risk factors identified in the study population.
  • The A allele (OR=1.27, P=0.04) and AA genotype (OR=1.86, P=0.02) of the -844 G>A polymorphism were significantly associated with ACS.
  • Recessive model analysis confirmed the association (OR=1.76, P=0.02).
  • A significant association was also found between the polymorphism and dyslipidemia in ACS patients (OR=1.99, P=0.04).

Conclusions:

  • The A allele and AA genotype of the -844 PAI-1 gene polymorphism are confirmed risk factors for ACS.
  • The AA genotype may play a role in the development of dyslipidemia among ACS patients.
  • This genetic variant represents a potential biomarker for ACS risk stratification.
Abstract

More Related Videos

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.8K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.4K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
481
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.2K